http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36497825

Outgoing Links

Predicate Object
contentType Multicenter Study|Journal Article|Research Support, Non-U.S. Gov't|Research Support, N.I.H., Extramural
endingPage 6588
issn 2473-9537
2473-9529
issueIdentifier 21
pageRange 6579-6588
publicationName Blood Advances
startingPage 6579
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_448c3d7a8b95445db230c0de0b6d375a
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f949477490c0a53ebdba999231d32b8b
bibliographicCitation Yamshon S, Chen GZ, Gribbin C, Christos P, Shah B, Schuster SJ, Smith SM, Svoboda J, Furman RR, Leonard JP, Martin P, Ruan J. Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood Adv. 2023 Nov 14;7(21):6579–88. PMID: 37682791; PMCID: PMC10641095.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d72e35e0550d7256fcc43b899821c93
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_191f9f901622232de240d4cd0276f4df
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_179fd7e0e2c7fb0e5e1f9012b28ed005
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d28a0d7084ece3f5d6fdbb90d4ed5bbe
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9893-4949
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5bd97971940eece0e105d782dfd1f95f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4adff06e07a03f0a84c00321948ae234
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e097012447d467a902c7dd335aa0a212
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_92e0e581b94360dcdb98dd95a589e161
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3376-8978
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d4060dd21f1b951874a6bd684c8de09a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3aaf1dd687abd6b3e8c33661c013f85b
date 2023-10-30^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1182/bloodadvances.2023010606
https://pubmed.ncbi.nlm.nih.gov/37682791
https://pubmed.ncbi.nlm.nih.gov/PMC10641095
isPartOf https://portal.issn.org/resource/ISSN/2473-9537
https://portal.issn.org/resource/ISSN/2473-9529
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/46065
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
discusses http://id.nlm.nih.gov/mesh/M0244307
http://id.nlm.nih.gov/mesh/M0479831
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D020522Q000473
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000077269Q000627
http://id.nlm.nih.gov/mesh/D058873
http://id.nlm.nih.gov/mesh/D000069283Q000009
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000971Q000009
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D005500

Showing number of triples: 1 to 44 of 44.